<DOC>
	<DOCNO>NCT01390714</DOCNO>
	<brief_summary>The purpose study investigate pharmacodynamics ( PD ) pharmacokinetics E3710 follow oral administration Healthy Male Japanese Subjects</brief_summary>
	<brief_title>Pharmacodynamic Pharmacokinetic Study E3710 Following Oral Administration Healthy , Male , Japanese Subjects</brief_title>
	<detailed_description>This study conduct healthy , male , Japanese subject use open-label , randomize , crossover design comparison multiple oral dos E3710 . Rabeprazole Esomeprazole use study market comparators . In arm , pharmacodynamics measure regard intragastric pH . The measurement record use pH probe esophageal measurement capability 24 hour post-dose . Pharmacokinetics measurement also conduct dose stage collect serial blood sample .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects receive full explanation objective content study provide write consent participate study free start screening . 2 . Japanese , healthy , male adult , 2040 year age day consent . 3 . Japanese subject must first generation Japanese ( born Japan Japanese parent Japanese grandparent ) , must live 5 year outside Japan must change life style habit , include diet , live outside Japan . 4 . CYP2C19 homo heterozygous extensive metabolizers . 5 . Subjects current infection Helicobacter pylorus ( H. pylorus ) . 6 . Subjects body mass index ( BMI ) 18.525.0 kg/m2 time screen . 7 . Subjects receive screen examination within 4 week enter Phase I unit Stage 1 judge eligible study investigator . Exclusion Criteria 1 . Likely allergy sensitivity component E3710 base know allergy drug class ( e.g . proton pump inhibitor , specifically RPZ EPZ ) opinion Principal Investigator might increase potential adverse event . 2 . Subjects present previous history drug allergy , food allergy clinically problematic allergy ( e.g . chronic asthma urticaria ) . 3 . Subjects diseases may affect evaluation study drug gastrointestinal , hepatic , renal , respiratory , endocrine , blood , nervous , mental cardiac vascular disease congenital metabolic disorder time screen within 4 week hospitalization stage study . 4 . Subjects history surgical therapy ( resection liver , kidney digestive tract ) may influence pharmacokinetics study drug . 5 . Subjects 10 % body weight change period screen Day 1 hospitalization stage study . 6 . Subjects beverages contain caffeine ( coffee , tea , chocolate cola ) within 72 hour hospitalization stage study . 7 . Subjects grapefruit juice food drink contain grapefruit within 72 hour hospitalization stage study . 8 . Subjects alcoholic beverage within 72 hour hospitalization stage study . 9 . Subjects quit smoke hospitalization . 10 . Subjects perform vigorous exercise hard labor ( 1 hour day 5 day week ) within 2 week hospitalization stage study . 11 . Subjects find abnormal clinical symptom organ function disorder require medical treatment examination medical history , symptom sign , vital sign , ECG laboratory test . 12 . Subjects QTC longer 450 msec 12lead electrocardiography ( Bazett 's method ) . 13 . Subjects history alcohol drug abuse , suspect history positive reaction urinary drug test time screen hospitalization study . 14 . Subjects use ethical drug within 4 week hospitalization stage study * . 15 . Subjects take OTC drug ( include PPIs H2receptor antagonist ) , antacid , nutrient , vitamin preparation preparation contain herb ( include Chinese medicine food product ) within one week hospitalization stage study . However , herb preparation , know induce cytochrome P450 , drug metabolizing enzyme ( e.g . preparation food product contain St. John 's wort ) , subject take preparation within 4 week hospitalization stage study . 16 . Subjects use investigational drug investigational medical equipment within 16 week hospitalization stage study . 17 . Subjects receive blood transfusion within 12 week hospitalization stage study , donate 400 mL whole blood within 12 week 200 mL whole blood within 4 week hospitalization stage study . 18 . Subjects infection require medical treatment within 4 week hospitalization stage study . 19 . Subjects positive hepatitis B surface antigen ( HBs antigen ) , hepatitis C virus ( HCV ) antibody qualitative test syphilis . 20 . Subjects diagnose acquired immunodeficiency syndrome ( AIDS ) positive reaction human immunodeficiency virus ( HIV ) . 21 . Subjects willing observe rule study observe . 22 . Patients judged inappropriate participation study investigator subinvestigator . * : Excluding drug prescribe investigator case necessity treatment adverse event hospitalization .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Proton Pump Inhibitors</keyword>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>